Head and Neck Cancer
A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BCA101X301)
- Details
ClinicalTrials.gov ID:
NCT06788990
Diagnosis Type:
NA
USOR Number:
- Address
,
P: